提供：ウエルスアドバイザー社Medorex <4586.T> rebounded for the first time in eight days, rising 9 yen to 77 yen at one point. After the close on the 2nd, the company announced that it had resubmitted a new drug application to the FDA (USA Food and Drug Administration) for "MRX-5LBT," a treatment for post-herpetic neuralgia co-developed with De-Westen Therapeutics Institute (DWTI) <4576.T>, which was viewed as a positive material.
According to the company, "MRX-5LBT" is a novel lidocaine patch utilizing the company's proprietary technology ILTS (Ionic Liquid Transdermal System). It aims to target the market of the lidocaine patch "Lidoderm" and is being developed with the goal of expanding into new markets.
As of 10:22 AM, the stock price stands at 74 yen, up 6 yen from the previous day.
Provided by Wealth Advisor Company.
